veltuzumab-IFN alpha 2b conjugate (IBC/Immunomedics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameveltuzumab-IFN alpha 2b conjugate (IBC/Immunomedics)
Drug Alias NameCk-20-2b20-2b-2b20-2b
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsInterferon alpha 2 ligand
TargetsInterferon alpha-2B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIbc Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIbc Pharmaceuticals IncImmunomedics Inc
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A